Address
75 State Street
Boston, MA 02109
United States of America (the)
Phone
457 070 5210
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
October 29, 2020
| Name | Title | Pay | Year Born |
| Hans T. Schambye | Co-Founder, President, Chief Executive Officer & Director | 1.03M | 1966 |
| Lori C. Firmani | Chief Financial Officer | 446,528 | 1974 |
| Becker Hewes | Chief Medical Officer | 528,064 | 1967 |
| Garrett Winslow | Senior Vice President, General Counsel & Corporate Secretary | 734,792 | 1980 |
| Matthew Kronmiller | EVice President of Strategy & Chief Business Officer | 0 | 1988 |
| Ulf J. Nilsson | Co-Founder | 0 | N/A |
| Sherwin Sattarzadeh | Interim Principal Executive Officer & COO | 0 | N/A |
| Hakon Leffler | Co-Founder | 0 | N/A |
| Tariq Sethi FRCP | Co-Founder | 0 | N/A |
Galecto, Inc. is a clinical-stage biotechnology company focused on creating new therapeutic agents for a range of illnesses, including fibrotic conditions, cancer, and inflammation. Its most advanced investigational drug, GB2064, is currently undergoing Phase IIa clinical studies to treat myelofibrosis. The company is also developing GB0139, an inhalable compound that targets galectin-3, which is in Phase IIb trials for severe fibrotic lung disorders, such as idiopathic pulmonary fibrosis (IPF)—a serious and progressively worsening lung disease. Additionally, Galecto is advancing GB1211, a selective oral galectin-3 inhibitor, with ongoing Phase IIa trials for cancer and Phase Ib/IIa trials for fibrosis. Founded in 2011, Galecto, Inc. is headquartered in Boston, Massachusetts.